Skip to main content
SpringerLink
Log in

Biological and target synthetic DMARDs have differing infection risks

  • Clinical study
  • Published:
Reactions Weekly Aims and scope

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Reference

  • Frisell T, et al. Safety of biological and targeted synthetic disease-modifying antirheumatic drugs for rheumatoid arthritis as used in clinical practice: results from the ARTIS programme. Annals of the Rheumatic Diseases : 14 Feb 2023. Available from: URL: http://doi.org/10.1136/ard-2022-223762

Download references

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Biological and target synthetic DMARDs have differing infection risks. Reactions Weekly 1945, 7 (2023). https://doi.org/10.1007/s40278-023-34088-6

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40278-023-34088-6

Search

Navigation